{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:00:00Z","timestamp":1791968400571,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00892-5","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:52:22Z","timestamp":1771678342000},"page":"1009-1031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient Perceptions of Needs and Expectations Regarding the Current Management of Myasthenia Gravis: A Biopsychosocial Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3384","authenticated-orcid":false,"given":"Francisco Javier","family":"Campos-Lucas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guerrero-Sola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"\u00c1lvarez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Pardo-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"G\u00f3mez-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ant\u00f3n-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Caballero-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"2","key":"892_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis. Neurol Clin. 2018;36(2):253\u201360.","journal-title":"Neurol Clin"},{"issue":"12","key":"892_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","volume":"134","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. J Clin Investig. 2024;134(12):e179742.","journal-title":"J Clin Investig"},{"key":"892_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"issue":"1","key":"892_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516.","journal-title":"J Transl Med"},{"key":"892_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071130","author":"A Aggelina","year":"2023","unstructured":"Aggelina A, Karampli E, Mavrovounis G, Boutsikos I, Pantazopoulos I, Kakavas S, et al. Evaluation of the quality of life of patients with myasthenia gravis in Greece. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13071130.","journal-title":"J Pers Med"},{"issue":"1","key":"892_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12(1):107\u201328.","journal-title":"Neurol Ther"},{"key":"892_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G, Cole C, Hughes T, Silvestri N, et al. The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci. 2022;437:120268.","journal-title":"J Neurol Sci"},{"issue":"4","key":"892_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s13760-022-01919-y","volume":"122","author":"A Akkan Suzan","year":"2022","unstructured":"Akkan Suzan A, Kahraman Koytak P, Uluc K, Tanridag T. Physical and mental fatigue in myasthenia gravis and its correlation with other symptoms. Acta Neurol Belg. 2022;122(4):915\u201323.","journal-title":"Acta Neurol Belg"},{"issue":"1","key":"892_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, Beauchamp J, Chiroli S, Quinn C, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13(1):e066445.","journal-title":"BMJ Open"},{"key":"892_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jocn.2020.06.023","volume":"79","author":"X Fan","year":"2020","unstructured":"Fan X, Xing C, Yang L, Wang J, Feng L. Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, China. J Clin Neurosci. 2020;79:84\u20139.","journal-title":"J Clin Neurosci"},{"issue":"4","key":"892_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5582\/irdr.2019.01121","volume":"8","author":"N Garz\u00f3n-Orjuela","year":"2019","unstructured":"Garz\u00f3n-Orjuela N, Van Der Werf L, Prieto-Pinto LC, Lasalvia P, Casta\u00f1eda-Cardona C, Rosselli D. Quality of life in refractory generalized myasthenia gravis: a rapid review of the literature. Intractable Rare Dis Res. 2019;8(4):231\u20138.","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"892_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40120-024-00617-6","volume":"13","author":"N Kawaguchi","year":"2024","unstructured":"Kawaguchi N, Tsuda K, Tanaka N, Kerstens R, Harada D. Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients\u2019 perspectives in Japan. Neurol Ther. 2024;13(4):1099\u2013113.","journal-title":"Neurol Ther"},{"issue":"2","key":"892_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1103\u201325.","journal-title":"Neurol Ther"},{"issue":"6","key":"892_CR14","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269(6):3050\u201363.","journal-title":"J Neurol"},{"key":"892_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11:553626.","journal-title":"Front Neurol"},{"issue":"1","key":"892_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12325-023-02704-w","volume":"41","author":"S Dewilde","year":"2024","unstructured":"Dewilde S, Phillips G, Paci S, De Ruyck F, Tollenaar NH, Janssen MF. The burden patients with myasthenia gravis experience in terms of breathing, fatigue, sleep, mental health, discomfort and usual activities in comparison to the general population. Adv Ther. 2024;41(1):271\u201391.","journal-title":"Adv Ther"},{"issue":"4","key":"892_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"3","key":"892_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"21","key":"892_CR19","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.3390\/jcm11216394","volume":"11","author":"D S\u00e1nchez-Tejerina","year":"2022","unstructured":"S\u00e1nchez-Tejerina D, Sotoca J, Llaurado A, L\u00f3pez-Diego V, Juntas-Morales R, Salvado M. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med. 2022;11(21):6394.","journal-title":"J Clin Med"},{"issue":"5","key":"892_CR20","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","volume":"271","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T, Tan X, Wang S, Qu R, et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2024;271(5):2298\u2013308.","journal-title":"J Neurol"},{"issue":"6","key":"892_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","volume":"18","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800\u20134.","journal-title":"Epidemiology"},{"key":"892_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103186","volume":"56","author":"E Moral-Torres","year":"2021","unstructured":"Moral-Torres E, Fern\u00e1ndez-Fern\u00e1ndez \u00d3, Caballero-Mart\u00ednez F, Carrascal-Rueda P, Monge-Mart\u00edn D, Campos-Lucas FJ. Patient experience and self-perceived biopsychosocial burden of people living with multiple sclerosis: an epidemiological survey (BPS-MuScle study) in Spain. Mult Scler Relat Disord. 2021;56:103186.","journal-title":"Mult Scler Relat Disord"},{"key":"892_CR23","volume-title":"Crawford slip method: how to mobilize brainpower by think tank technology","author":"CC Crawford","year":"1983","unstructured":"Crawford CC, Demidovich JW. Crawford slip method: how to mobilize brainpower by think tank technology. Los Angeles: School of Public Administration, University of Southern California; 1983."},{"issue":"5","key":"892_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"key":"892_CR25","unstructured":"World Health Organization (WHO). Health promotion glossary. Ginebra: Organizaci\u00f3n Mundial de la Salud; 1998 [citado 11 dic 2025]. Disponible en: https:\/\/iris.who.int\/handle\/10665\/64546. Accessed 11 Dec 2025."},{"key":"892_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev.soc.27.1.363","volume":"27","author":"BG Link","year":"2001","unstructured":"Link BG, Phelan JC. Conceptualizing stigma. Annu Rev Sociol. 2001;27:363\u201385.","journal-title":"Annu Rev Sociol"},{"issue":"5","key":"892_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16233","volume":"31","author":"I Engebretsen","year":"2024","unstructured":"Engebretsen I, Gilhus NE, Kristiansen IS, S\u00e6ther EM, Lindberg-Schager I, Arneberg F, et al. The epidemiology and societal costs of myasthenia gravis in\u00a0Norway: a non-interventional study using national registry\u00a0data. Eur J Neurol. 2024;31(5):e16233.","journal-title":"Eur J Neurol"},{"issue":"1","key":"892_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12883-024-03553-y","volume":"24","author":"J McCallion","year":"2024","unstructured":"McCallion J, Borsi A, Noel W, Lee J, Karmous W, Sattler S, et al. Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. BMC Neurol. 2024;24(1):61.","journal-title":"BMC Neurol"},{"key":"892_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1072861","volume":"13","author":"X Wu","year":"2023","unstructured":"Wu X, Li RY, Ye XB, Wang N. Reduced quality of life in myasthenia gravis patients: a study on 185 patients from China. Front Neurol. 2023;13:1072861.","journal-title":"Front Neurol"},{"issue":"9","key":"892_CR30","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","volume":"27","author":"G Hernandez","year":"2018","unstructured":"Hernandez G, Garin O, Pardo Y, Vilagut G, Pont \u00c0, Su\u00e1rez M, et al. Validity of the EQ-5D-5L and reference norms for the Spanish population. Qual Life Res. 2018;27(9):2337\u201348.","journal-title":"Qual Life Res"},{"issue":"2","key":"892_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, Ramos-Go\u00f1i JM, Vilagut G, K\u00f6nig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205\u201316.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"892_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023;2(1):e000241.","journal-title":"BMJ Med"},{"key":"892_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538\/full","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol [Internet]. 2020. https:\/\/doi.org\/10.3389\/fneur.2020.00538\/full.","journal-title":"Front Neurol [Internet]"},{"issue":"6","key":"892_CR34","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","volume":"41","author":"C van Steen","year":"2024","unstructured":"van Steen C, Celico L, Spaepen E, Hagenacker T, Meuth SG, Ruck T, et al. Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis: indirect treatment comparison. Adv Ther. 2024;41(6):2486\u201399.","journal-title":"Adv Ther"},{"issue":"3","key":"892_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, et al. Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan. Neurol Clin Pract. 2024;14(3):e200276.","journal-title":"Neurol Clin Pract"},{"key":"892_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1307627","volume":"14","author":"M Stein","year":"2023","unstructured":"Stein M, Grittner U, Stegherr R, Gerischer L, Stascheit F, Hoffmann S, et al. The burden of myasthenia gravis - highlighting the impact on family planning and the role of social support. Front Neurol. 2023;14:1307627.","journal-title":"Front Neurol"},{"key":"892_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22078-3","volume":"12","author":"D Marbin","year":"2022","unstructured":"Marbin D, Piper SK, Lehnerer S, Harms U, Meisel A. Mental health in myasthenia gravis patients and its impact on caregiver burden. Sci Rep. 2022;12:19275.","journal-title":"Sci Rep"},{"issue":"4","key":"892_CR38","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mus.28063","volume":"69","author":"J Pesa","year":"2024","unstructured":"Pesa J, Choudhry Z, de Courcy J, Barlow S, Chatterton E, Thomas O, et al. The impact of myasthenia gravis severity on work and daily activities. Muscle Nerve. 2024;69(4):428\u201339.","journal-title":"Muscle Nerve"},{"key":"892_CR39","unstructured":"Spain: Country Health Profile 2023 | European Observatory on Health Systems and Policies [Internet]. [cited 2024 Sep 9]. https:\/\/eurohealthobservatory.who.int\/publications\/m\/spain-country-health-profile-2023. Accessed 11 Dec 2025."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00892-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:08:04Z","timestamp":1778681284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00892-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["892"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00892-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francisco Javier Campos-Lucas, Elena Cort\u00e9s-Vicente, Antonio Guerrero-Sola, Rodrigo \u00c1lvarez-Velasco, Raquel Pardo-G\u00f3mez, Juan G\u00f3mez-Salgado, Cristina Ant\u00f3n-Rodr\u00edguez and Fernando Caballero-Mart\u00ednez declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study adhered to the ethical principles outlined in the Declaration of Helsinki (Fortaleza revision) and Spanish Law 14\/2007 on biomedical research. The protocol was reviewed and approved by the Ethics Committee of Hospital de la Santa Creu I Sant Pau, Barcelona, Spain (Code UCIS-MG-2022-03).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}